arXivDaily arXiv每日学术速递 周一至周五更新
arXiv 2601.05151stat.MLcs.LG
收藏

ROOFS:稳健的生物标志物特征选择

ROOFS: RObust biOmarker Feature Selection

Inria(法国国家信息与自动化技术研究院);Inserm(法国国家健康与医学研究中心);Centre Inria Sophia Antipolis - Méditerranée(Inria 南法地中海研究中心);Centre de Recherches en Cancérologie de Marseille(马赛癌症研究中心);Inserm U1068;CNRS UMR7258(国家科学研究中心UMR7258);Institut Paoli-Calmettes(Paoli-Calmettes研究所);Pharmacy faculty, Aix-Marseille University(阿维尼翁-马赛大学药学院);Veracyte SAS(Veracyte SAS公司);Assistance Publique-Hôpitaux de Marseille (APHM)(马赛公共医院 (APHM));Gustave Roussy(Gustave Roussy研究所)

Anastasiia Bakhmach, Paul Dufossé, Simon Charpigny, Florence Monville, Laurent Greillier, Fabrice Barlési, Sébastien Benzekry

AI总结:

针对生物医学数据特征选择难题,提出ROOFS Python包,在肺癌抗PD-(L)1免疫治疗耐药预测数据上对多种特征选择方法基准测试,评估23种方法与11种分类器组合,确定最优方法,可提高特征选择可重复性与临床模型转化价值。

摘要:

特征选择对于生物标志物发现和临床预测建模至关重要。过去几十年,特征选择方法文献丰富成熟,但未完全应用于生物医学研究。生物医学数据存在高维特征空间、低样本量等挑战,使特征选择不易。我们提出ROOFS,一个Python包,能在用户数据上对多种特征选择方法进行基准测试并生成报告。我们在肺癌抗PD-(L)1免疫治疗耐药预测的PIONeeR临床试验数据上展示了ROOFS的效用,评估了23种方法与11种分类器组合,确定了基于t检验和逻辑回归的Benjamini-Hochberg错误发现率调整p值联合的过滤器为最优方法,优于包括LASSO在内的其他方法。我们得出结论,使用ROOFS进行全面基准测试有可能提高特征选择发现的可重复性并增加临床模型的转化价值。

英文摘要:

Feature selection (FS) is essential for biomarker discovery and clinical predictive modeling. Over the past decades, methodological literature on FS has become rich and mature, offering a wide spectrum of algorithmic approaches. However, much of this methodological progress has not fully translated into applied biomedical research. Moreover, challenges inherent in biomedical data, such as high-dimensional feature space, low sample size, multicollinearity, and missing values, make FS non-trivial. To help bridge this gap between methodological development and practical application, we propose ROOFS (RObust biOmarker Feature Selection), a Python package available at https://gitlab.inria.fr/compo/roofs, designed to help researchers in the choice of FS method adapted to their problem. ROOFS benchmarks multiple FS methods on the user's data and generates reports summarizing a comprehensive set of evaluation metrics, including downstream predictive performance estimated using optimism correction, stability, robustness of individual features, and true positive and false positive rates assessed on semi-synthetic data with a simulated outcome. We demonstrate the utility of ROOFS on data from the PIONeeR clinical trial, aimed at identifying predictors of resistance to anti-PD-(L)1 immunotherapy in lung cancer. Of the 34 FS methods gathered in ROOFS, we evaluated 23 in combination with 11 classifiers (253 models) and identified a filter based on the union of Benjamini-Hochberg false discovery rate-adjusted p-values from t-test and logistic regression as the optimal approach, outperforming other methods including widely used LASSO. We conclude that comprehensive benchmarking with ROOFS has the potential to improve the reproducibility of FS discoveries and increase the translational value of clinical models.

机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。

↑